ERα

Overview

Estrogen receptor alpha (ERα), encoded by the ESR1 gene, is a ligand-activated nuclear transcription factor and a member of the nuclear receptor superfamily. Upon binding to its primary ligand, 17β-estradiol, ERα undergoes conformational change, dimerization, and translocation to the nucleus, where it modulates the transcription of estrogen-responsive genes involved in cell proliferation, differentiation, survival, and metabolic homeostasis. ERα is expressed in a wide range of tissues, including the mammary gland, uterus, bone, cardiovascular system, and brain, where it mediates diverse physiological effects ranging from reproductive function and bone density maintenance to neuroprotection and cognitive regulation.

From a clinical standpoint, ERα occupies a central role in hormone-dependent malignancies. Approximately 70–80% of breast cancers express ERα, and its sustained transcriptional activity is a principal driver of tumor growth in luminal subtypes. This has made ERα one of the most thoroughly validated oncology drug targets, with therapeutic strategies including selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors designed to attenuate its signaling axis. Beyond oncology, ERα agonism has attracted growing interest in neuroprotection, reflecting the receptor's documented roles in synaptic plasticity, neuroinflammation, and cognitive function.

Focus of Latest Publications

Recent publications highlight ERα as an active subject of investigation across two broad domains: breast cancer drug resistance and neurological protection, with complementary lines of inquiry pursuing both ERα activation and ERα degradation as therapeutic strategies depending on clinical context.

In the neurological domain, a 2026 study published in CNS Neuroscience & Therapeutics (PMID: 42212628) examined whether ERα activation could protect aged female mice against cognitive deficits induced by sevoflurane, a volatile anesthetic known to cause hippocampal synaptic injury in vulnerable populations. The study focused on PTEN — a well-characterized tumor suppressor and phosphatase — and its nuclear translocation as a mediating mechanism of sevoflurane neurotoxicity. The investigators demonstrated that activation of ERα was capable of mitigating sevoflurane-induced hippocampal synaptic and cognitive deficits, implicating ERα agonism as a neuroprotective strategy that operates at least in part through modulation of PTEN nuclear translocation. This finding positions ERα not merely as an oncology target but as a plausible therapeutic lever in anesthesia-related neurotoxicity, particularly in aged female patients.

On the oncology side, two distinct studies addressed the problem of endocrine resistance in ERα-positive breast cancer. A 2026 report in Angewandte Chemie (PMID: 42189698) described the rational design of hydrophobic tag (HyT)-based targeted protein degraders that selectively eliminate ERα through the proteasomal pathway. By conjugating hydrophobic amino acid tags to ERα-targeting ligands via alkane linkers of variable lengths, the authors identified a lead compound (VI-10h) capable of recruiting an HSP27-mediated E3 ligase complex to drive ERα degradation. Crucially, this degradation strategy was shown to overcome endocrine-resistant breast cancer phenotypes — a significant limitation of conventional aromatase inhibitors — offering a mechanistic alternative to classical receptor blockade. A parallel 2026 study in Clinical Epigenetics (PMID: 42050691) investigated GLYATL1, a gene associated with metabolic and epigenetic reprogramming, in the context of luminal breast cancer. The study underscored that ERα-positive luminal breast cancer, while typically treated with aromatase inhibitors, frequently develops resistance that limits long-term therapeutic success. GLYATL1 was identified as a factor associated with endocrine resistance through epigenetic changes, further elaborating the molecular landscape that undermines ERα-Targeted therapies.

From a computational and natural product perspective, a 2026 study in Biochemical and Biophysical Research Communications (PMID: 41819753) examined ERα alongside p38α and p38γ kinases as co-targets for bioactive compounds derived from royal jelly, including chrysin, a naturally occurring flavonoid. Through extensive in silico profiling, the study characterized ERα's structural suitability as a drug target, identifying its binding pocket and demonstrating favorable interactions with royal jelly-derived compounds. This work integrates ERα into a multi-target anti-breast cancer framework, suggesting that natural products capable of simultaneously modulating ERα and stress-activated kinases may hold therapeutic potential.

Key Publications

• Jun ERα Agonist Protects Aged Female Mice From Sevoflurane Neurotoxicity via PTEN Nuclear Translocation. (CNS neuroscience & therapeutics, 2026, PMID 42212628): "This study aimed to investigate whether PTEN nuclear translocation mediates sevoflurane-induced hippocampal synaptic and cognitive deficits in aged female mice, and whether activation of ERα can mitigate these effects."
• May Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation. (Angewandte Chemie (International ed. in English), 2026, PMID 42189698): "Herein, we designed structurally optimized HyT-based degraders by covalently conjugating hydrophobic amino acid tags to ERα-targeting ligands via alkane linkers of varying lengths, identifying the lead compound VI-10h."
• May GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer. (Clinical epigenetics, 2026, PMID 42050691): "Estrogen receptor alpha (ERα)-positive luminal breast cancer is commonly treated with aromatase inhibitors (AI) to block estrogen signaling; however, resistance frequently develops, limiting therapy success."
• May Targeting p38α, p38γ, and ERα with bioactive compounds from royal jelly for anti-breast cancer activity: A comprehensive in-silico study using fingerprint analysis, molecular dynamics, MEP, and PCA. (Biochemical and biophysical research communications, 2026, PMID 41819753): "The results revealed that p38α, p38γ, and ERα were structurally suitable for investigation and were successfully characterized through fingerprint analysis and binding pocket prediction."